{"id":131820,"title":"GENinCode plc (AIM: GENI) shares plunge 40% after deeply discounted placing","publisher":"Share Talk","author":"sharetalk","published":"2026-01-22T12:10:34+00:00","modified":"2026-01-22T12:15:36+00:00","canonical_url":"https://www.share-talk.com/genincode-plc-aim-geni-shares-plunge-40-after-deeply-discounted-placing/","markdown_url":"https://www.share-talk.com/genincode-plc-aim-geni-shares-plunge-40-after-deeply-discounted-placing.md","json_url":"https://www.share-talk.com/genincode-plc-aim-geni-shares-plunge-40-after-deeply-discounted-placing.json","category":"Health","categories":["Health","Healthcare","Pharmaceutical"],"tags":["Bernard Conrad","CARDIO","Catalonia","coronary heart disease","Genesupport","GENI","Genincode","inCode-Score®","laboratories","Matthew Walls","New York","NYSDOH","ovarian cancer","Oxford","ROCA Test","Spain","Switzerland","US revenues","USA"],"featured_image":"https://i0.wp.com/www.share-talk.com/wp-content/uploads/2026/01/GP99eq7WwAA9ZZB-750x406-1.webp?fit=750%2C406&quality=80&ssl=1","format":"news","language":"en-GB","content":"**GENinCode plc (AIM: GENI)** has conditionally raised £3.9m in gross proceeds through the issue of 388,145,000 new ordinary shares at 1p each, representing a 47.4pc discount to the closing middle market price of 1.90 pence per Ordinary Shares on 20 January 2026, being the last business day prior to the announcement of the Fundraising.\n\nDirectors of the company participated in the fundraising, subscribing for a total of 23,000,000 new shares.\n\nGENinCode said it expects to announce the outcome of its retail offer on January 26, 2026. Admission of the new shares to trading on **AIM** is anticipated on or around February 11, 2026, subject to shareholder approval.\n\nA general meeting has been scheduled for February 9, 2026, at which shareholders will be asked to approve the resolutions required to complete the fundraising."}